Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Genetic deficiency in Pparg does not alter development of experimental prostate cancer

Abstract

The role of the nuclear peroxisome proliferator–activated receptor (PPAR)-γ in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor. We have directly tested this notion using a mouse model of prostate cancer. Neither hemizygous deletion of Pparg nor complete ablation of Ppara influenced the development of prostate cancer in our experimental context.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Gene expression analysis and pathology of Pparg hemizygous tumors.

Similar content being viewed by others

References

  1. Lefebvre, A.M. et al. Nat. Med. 4, 1053–1057 (1998).

    Article  CAS  Google Scholar 

  2. Saez, E. et al. Nat. Med. 4, 1058–1061 (1998).

    Article  CAS  Google Scholar 

  3. Sarraf, P. et al. Nat. Med. 4, 1046–1052 (1998).

    Article  CAS  Google Scholar 

  4. Sarraf, P. et al. Mol. Cell 3, 799–804 (1999).

    Article  CAS  Google Scholar 

  5. Mueller, E. et al. Proc. Natl. Acad. Sci. USA 97, 10990–10995 (2000).

    Article  CAS  Google Scholar 

  6. Huss, W.J., Maddison, L.A. & Greenberg, N.M. Semin. Cancer Biol. 11, 245–260 (2001).

    Article  CAS  Google Scholar 

  7. Collett, G.P. et al. Clin. Cancer Res. 6, 3241–3248 (2000).

    CAS  PubMed  Google Scholar 

  8. Paltoo, D. et al. Cancer Lett. 191, 67–74 (2003).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by CaP CURE and the Howard Hughes Medical Institute. The experiments were conducted in accordance with National Institutes of Health guidelines, with the approval of The Salk Institute's animal care committee. R.M.E. is an Investigator of the Howard Hughes Medical Institute for Biological Studies and March of Dimes Chair in Molecular and Developmental Biology.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ronald M Evans.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saez, E., Olson, P. & Evans, R. Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat Med 9, 1265–1266 (2003). https://doi.org/10.1038/nm928

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm928

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing